Eligen® Technology for Oral Delivery of Proteins and Peptides

  • Sunita Prem Victor
  • Willi Paul
  • Chandra Prakash Sharma
Chapter

Abstract

The Eligen® technology, an oral delivery technology, is based on the design and development of proprietary delivery carriers referred to as Emisphere delivery agents. The major limitations for noninvasive delivery such as rapid metabolism, chemical instability, and minimal absorption through gastrointestinal (GI) tract are overcome by the application of these delivery agents. Most of the delivery agents consist of amino acids having a molecular weight of 250–300 Da that are structurally diverse with different physiochemical properties. They facilitate the absorption of macromolecules through a transcellular mechanism. These agents have been evaluated for their ability to enhance the delivery of a wide range of therapeutic macromolecules. This review discusses the major challenges and strategies employed to overcome these difficulties. It also focuses on the application of novel proprietary delivery agents that have enabled the oral delivery of a large number of therapeutic proteins and peptides.

Keywords

Eligen® Macromolecules Absorption Transcellular Sodium N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC) Calcitonin Insulin Heparin Human growth hormone Vitamin B12 Parathyroid hormone 

References

  1. 1.
    Donovan MD, Flynn GL, Amidon GL. Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm Res. 1990;7(8):863–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Aungst BJ. Absorption enhancers: applications and advances. AAPS J. 2012;14(1):10–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Woodley JF. Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst. 1994;11(2–3):61–95.PubMedGoogle Scholar
  4. 4.
    Lipka E, Crison J, Amidon GL. Transmembrane transport of peptide type compounds: prospects for oral delivery. J Control Release. 1996;39(2–3):121–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Yun Y, Cho YW, Park K. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv Drug Deliv Rev. 2013;65(6):822–32.PubMedCrossRefGoogle Scholar
  6. 6.
    He C, et al. Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs. Biomaterials. 2012;33(33):8569–78.PubMedCrossRefGoogle Scholar
  7. 7.
    Griffin BT, O’Driscoll CM. Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies. Ther Deliv. 2011;2(12):1633–53.PubMedCrossRefGoogle Scholar
  8. 8.
    Rekha MR, Sharma CP. Oral delivery of therapeutic protein/peptide for diabetes—future perspectives. Int J Pharm. 2013;440(1):48–62.PubMedCrossRefGoogle Scholar
  9. 9.
    Muller G. Oral delivery of protein drugs: driver for personalized medicine. Curr Issues Mol Biol. 2011;13(1):13–24.PubMedGoogle Scholar
  10. 10.
    Werle M, Makhlof A, Takeuchi H. Oral protein delivery: a patent review of academic and industrial approaches. Recent Pat Drug Deliv Formul. 2009;3(2):94–104.PubMedCrossRefGoogle Scholar
  11. 11.
    Shaji J, Patole V. Protein and peptide drug delivery: oral approaches. Indian J Pharm Sci. 2008;70(3):269–77.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug delivery. J Control Release. 2011;153(2):106–16.PubMedCrossRefGoogle Scholar
  13. 13.
    Malik DK, et al. Recent advances in protein and peptide drug delivery systems. Curr Drug Deliv. 2007;4(2):141–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Park K, Kwon IC, Park K. Oral protein delivery: current status and future prospect. React Funct Polym. 2011;71(3):280–7.CrossRefGoogle Scholar
  15. 15.
    Fasano A. Novel approaches for oral delivery of macromolecules. J Pharm Sci. 1998;87(11):1351–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003;2(4):289–95.PubMedCrossRefGoogle Scholar
  17. 17.
    Henry CM. Special delivery. Chem Eng News. 2000;78(38):49–65.CrossRefGoogle Scholar
  18. 18.
    Leone-Bay A, et al. Oral delivery of biologically active parathyroid hormone. Pharm Res. 2001;18(7):964–70.PubMedCrossRefGoogle Scholar
  19. 19.
    Wu SJ, Robinson JR. Transport of human growth hormone across Caco-2 cells with novel delivery agents: evidence for P-glycoprotein involvement. J Control Release. 1999;62(1–2):171–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Leone-Bay A, et al. Compounds and compositions for delivering active agents, U.S. Patent, Editor. 2003, Emisphere Technologies Inc.: US.Google Scholar
  21. 21.
    Mlynek GM, Calvo LJ, Robinson JR. Carrier-enhanced human growth hormone absorption across isolated rabbit intestinal tissue. Int J Pharm. 2000;197(1–2):13–21.PubMedCrossRefGoogle Scholar
  22. 22.
    Wu SJ, Robinson JR. Transcellular and lipophilic complex-enhanced intestinal absorption of human growth hormone. Pharm Res. 1999;16(8):1266–72.PubMedCrossRefGoogle Scholar
  23. 23.
    Bagger YZ, et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone. 2005;37(3):425–30.PubMedCrossRefGoogle Scholar
  24. 24.
    Buclin T, et al. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res. 2002;17(8):1478–85.PubMedCrossRefGoogle Scholar
  25. 25.
    Hamdy RC, Daley DN. Oral calcitonin. Int J Womens Health. 2012;4:471–9.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Karsdal MA, et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthr Cartilage. 2010;18(2):150–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Karsdal MA, et al. The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos Int. 2008;19(9):1355–61.PubMedCrossRefGoogle Scholar
  28. 28.
    Karsdal MA, et al. Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. BMC Clin Pharmacol. 2008;8:12.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Karsdal MA, et al. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon calcitonin. BMC Clin Pharmacol. 2008;8:5.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Tanko LB, et al. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res. 2004;19(9):1531–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Baughman RA, et al. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Circulation. 1998;98(16):1610–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Brayden D, et al. Heparin absorption across the intestine: effects of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in Caco-2 monolayers. Pharm Res. 1997;14(12):1772–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Gonze MD, et al. Orally administered heparin for preventing deep venous thrombosis. Am J Surg. 1998;176(2):176–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Malkov D, et al. Pathway of oral absorption of heparin with sodium N-[8-(2-hydroxybenzoyl)amino] caprylate. Pharm Res. 2002;19(8):1180–4.PubMedCrossRefGoogle Scholar
  35. 35.
    Rivera TM, et al. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: pharmacological considerations. Pharm Res. 1997;14(12):1830–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Kidron M, et al. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabet Med. 2004;21(4):354–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Abbas R, et al. Oral insulin: pharmacokinetics and pharmacodynamics of human insulin following oral administration of an insulin/delivery agent capsule in healthy volunteers. Diabetes. 2002;51:A48.Google Scholar
  38. 38.
    Hoffman A, Qadri B. Eligen insulin—a system for the oral delivery of insulin for diabetes. IDrugs. 2008;11(6):433–41.PubMedGoogle Scholar
  39. 39.
    Kapitza C, et al. Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes. Diabetes Care. 2010;33(6):1288–90.PubMedCrossRefGoogle Scholar
  40. 40.
    Malkov D, et al. Oral delivery of insulin with the eligen technology: mechanistic studies. Curr Drug Deliv. 2005;2(2):191–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Leone-Bay A, et al. 4-[4-[(2-Hydroxybenzoyl)amino]phenyl]butyric acid as a novel oral delivery agent for recombinant human growth hormone. J Med Chem. 1996;39(13):2571–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Castelli MC, et al. SNAC co-formulation produces significant enhancement of oral vitamin B12 bioavailability in rats. FASEB J. 2008;22:795.Google Scholar
  43. 43.
    Milstein SJ, et al. Partially unfolded proteins efficiently penetrate cell membranes–implications for oral drug delivery. J Control Release. 1998;53(1–3):259–67.PubMedCrossRefGoogle Scholar
  44. 44.
    Alani AW, Robinson JR. Mechanistic understanding of oral drug absorption enhancement of cromolyn sodium by an amino acid derivative. Pharm Res. 2008;25(1):48–54.PubMedCrossRefGoogle Scholar
  45. 45.
    Azria M, Copp DH, Zanelli JM. 25 years of salmon calcitonin: from synthesis to therapeutic use. Calcif Tissue Int. 1995;57(6):405–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Lee YH, Sinko PJ. Oral delivery of salmon calcitonin. Adv Drug Deliv Rev. 2000;42(3):225–38.PubMedCrossRefGoogle Scholar
  47. 47.
    Gschwind HP, et al. Metabolism and disposition of the oral absorption enhancer 14C-radiolabeled 8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC) in healthy postmenopausal women and supplementary investigations in vitro. Eur J Pharm Sci. 2012;47(1):44–55.PubMedCrossRefGoogle Scholar
  48. 48.
    Bagger YZ, et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: A new potential treatment of osteoarthritis. Bone. 2005;37(3):425–30.PubMedCrossRefGoogle Scholar
  49. 49.
    Dinh S, Liu P, Wong V. Gastric absorption of oral insulin in rats, in Annual Meeting of American Association of Pharmaceutical Scientists. Toronto: American Association of Pharmaceutical Scientists; 2002.Google Scholar
  50. 50.
    Malkov D, Wang H-Z, Angelo R. Mechanism of oral absorption of insulin with Emisphere drug delivery agents, in The 29th Annual Meeting of Controlled Release Society. Seoul: Controlled Release Society; 2002.Google Scholar
  51. 51.
    Arbit E, et al. Oral insulin as first-line therapy in type 2 diabetes: a randomized-controlled pilot study. Diabetologia. 2004;47:A5.Google Scholar
  52. 52.
    Hirsh J, et al. Guide to anticoagulant therapy: Heparin a statement for healthcare professionals from the American Heart Association. Circulation. 2001;103(24):2994–3018.PubMedCrossRefGoogle Scholar
  53. 53.
    Leone-Bay A, Paton DR, Weidner JJ. The development of delivery agents that facilitate the oral absorption of macromolecular drugs. Med Res Rev. 2000;20(2):169–86.PubMedCrossRefGoogle Scholar
  54. 54.
    Leone-Bay A, et al. Oral delivery of rhGH: preliminary mechanistic considerations. Drug News Perspect. 1996;9(10):586–91.Google Scholar
  55. 55.
    Castelli MC, et al. Comparing the efficacy and tolerability of a new daily oral vitamin B-12 formulation and intermittent intramuscular vitamin B-12 in normalizing low cobalamin levels: a randomized, open-label, parallel-group study. Clin Ther. 2011;33(3):358–71.PubMedCrossRefGoogle Scholar
  56. 56.
    Molina E, et al. The effect of parathyroid hormone (hPTH 1–34) on oxytocin-induced contractions of pregnant human myometrium “in vitro”. FASEB J. 1996;10(3):3800.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Sunita Prem Victor
    • 1
  • Willi Paul
    • 1
  • Chandra Prakash Sharma
    • 1
  1. 1.Biomedical Technology WingSree Chitra Tirunal Institute for Medical Sciences and TechnologyThiruvananthapuramIndia

Personalised recommendations